Daniela De Rocco Selected Research

MYH9-Related Disorders

2/2019	MYH9-Related Thrombocytopenia: Four Novel Variants Affecting the Tail Domain of the Non-Muscle Myosin Heavy Chain IIA Associated with a Mild Clinical Evolution of the Disorder.
2/2014	MYH9-related disease: a novel prognostic model to predict the clinical evolution of the disease based on genotype-phenotype correlations.
1/2013	MYH9-related disease: five novel mutations expanding the spectrum of causative mutations and confirming genotype/phenotype correlations.
9/2010	A G to C transversion at the last nucleotide of exon 25 of the MYH9 gene results in a missense mutation rather than in a splicing defect.
4/2010	MYH9 related disease: four novel mutations of the tail domain of myosin-9 correlating with a mild clinical phenotype.
12/2009	Megakaryocyte and platelet abnormalities in a patient with a W33C mutation in the conserved SH3-like domain of myosin heavy chain IIA.
7/2009	Identification of the first duplication in MYH9-related disease: a hot spot for unequal crossing-over within exon 24 of the MYH9 gene.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Daniela De Rocco Research Topics

Disease

8	Thrombocytopenia (Thrombopenia) 02/2019 - 12/2009
7	MYH9-Related Disorders 02/2019 - 07/2009
4	Hemorrhage 01/2018 - 03/2011
2	Deafness (Deaf Mutism) 02/2019 - 12/2009
2	Cataract (Cataracts) 02/2019 - 12/2009
2	Infections 01/2018 - 01/2013
2	Neoplasms (Cancer) 01/2016 - 01/2013
2	Bernard-Soulier Syndrome (Giant Platelet Syndrome) 09/2014 - 03/2011
1	COVID-19 09/2020
1	Congenital amegakaryocytic thrombocytopenia 01/2018
1	Bone Marrow Failure Disorders 01/2018
1	Cytopenia 01/2016
1	Fanconi Anemia (Fanconi's Anemia) 01/2016
1	Mycoses (Diseases, Fungus) 05/2015
1	Nephritis 12/2009

Drug/Important Bio-Agent (IBA)

4	Nonmuscle Myosin Type IIAIBA 01/2013 - 07/2009
3	Myosin Heavy Chains (Myosin Heavy Chain)IBA 02/2019 - 12/2009
3	Thrombopoietin (c-mpl Ligand)IBA 01/2018 - 06/2011
2	von Willebrand FactorIBA 09/2014 - 03/2011
1	Hormones (Hormone)IBA 09/2020
1	Angiotensin-Converting Enzyme 2IBA 09/2020
1	EnzymesIBA 02/2019
1	4,5,6,7- tetrahydroisoxazolo(4,5- c)pyridin- 3- ol (THPO)IBA 01/2018
1	romiplostim FDA Link 01/2018
1	Fibrinogen (Factor I)FDA Link 11/2016
1	Biological ProductsIBA 01/2016
1	NucleotidesIBA 05/2015
1	Interleukin-17 (Interleukin 17)IBA 05/2015
1	Protein Isoforms (Isoforms)IBA 02/2014
1	Cytochromes c (Cytochrome c)IBA 02/2014
1	AntigensIBA 01/2013
1	DNA (Deoxyribonucleic Acid)IBA 01/2013
1	5' Untranslated Regions (5' UTR)IBA 01/2011

Therapy/Procedure

2	Hematopoietic Stem Cell Transplantation 01/2018 - 01/2016
1	Therapeutics 01/2018
1	Hysterectomy 08/2014
1	Blood Transfusion (Blood Transfusions) 08/2014